Platinum Global Solutions Limited
Copyright © PGS 2026 | All Rights Reserved
Platinum Global Solutions Limited. Registered in UK
PGS: Can you briefly introduce your company?
Answer: At Acnos Pharma, we act as an extension of your team, delivering dependable, customized support for pre-clinical through Phase I–III trials. Our global sourcing network ensures timely access to commercial drugs, comparators and ancillaries, all managed with precision and care. From cartons to compliance – we ensure your clinical products are securely packaged, correctly labeled and fully trial-ready. Our precision workflows keep your timelines intact and your data reliable.
PGS: Highlight your core services and solutions within the pharma and clinical supply ecosystem?
Answer: We provide global access to comparator drugs, ancillaries and unlicensed medicines through a flexible, quality-driven sourcing model. Whether for single-country studies or complex, multi-region trials – we deliver what you need, when you need it.
Our sourcing solutions reduce complexity and support trial continuity through efficient, just-in-time delivery and expert logistics management.
PGS: Which markets and regions do you primarily operate in, and how do these geographies influence your service capabilities?
Answer: In a highly regulated and complex environment, country-specific sourcing strategies are critical to the success of international clinical trials. Acnos Pharma combines global reach with local compliance expertise to deliver tailor-made solutions that go far beyond standard supply.
We ensure that your trial supplies are not only available where needed, but also fully compliant with local requirements – reducing cost, avoiding delays, and keeping your study on track.
PGS: What differentiates your solutions from others in the industry, and how do you bring value to pharma clients, CROs, and CDMOs?
Answer: Our sourcing capabilities differentiate us through a combination of a great manufacturer and supplier network, global reach, precision, and agility to support clinical trials and the possibility to do adhoch labelling for these sourced products in our GMP facility in Aachen, Germany. Below are the key elements that set us apart:
We maintain a broad global network of manufacturers (>150 MAH), wholesalers, and licensed distributors, allowing us to source commercial medications—including comparators, biosimilars, and rescue medications—across multiple geographies. This enables us:
We ensure full compliance with country-specific requirements for importation, labeling, and distribution. This includes:
Together with our sponsors and partners we can optimize sourcing timelines to minimize waste, expiries and overage depending on the study forecast and current enrollment numbers.
We create sourcing assessments and strategies with built-in contingencies, including:
We view sourcing not just as procurement, but as a strategic lever to ensure patient safety across the clinical lifecycle, supply continuity and trial speed.
PGS: What major challenges do you foresee for the pharma and clinical supply chain in the coming years, and how is your organization positioned to support and complement industry needs?
Answer: The coming years will bring unprecedented complexity to the pharmaceutical and clinical supply chain — from increased globalization of studies and evolving regulatory landscapes to limited product availability and growing expectations for speed, transparency, and sustainability. These challenges demand partners who combine compliance and reliability with true agility. At Acnos, we see these developments not as obstacles, but as opportunities to create value for our partners. Our sourcing model is built on a global network of over 150 manufacturers (MAHs), accompanied by wholesalers, and licensed distributors, giving us the ability to access even hard-to-source or limited-supply medications directly from manufacturers or through the open market. This ensures short, efficient supply routes and the flexibility to shift rapidly between products or sourcing strategies when market conditions change. In essence, our global reach, precision, and responsiveness empower sponsors to navigate the evolving clinical landscape with confidence — ensuring that patients receive the right medication, at the right time, anywhere in the world.
PGS: How do you see the future of clinical research, logistics, and pharma operations evolving, and what role does your organization aim to play in shaping this future?
Answer: The future of clinical research and pharmaceutical operations is moving toward a model defined by complexity, connectivity, and agility. As trials become increasingly global, decentralised, and data-driven, supply chains must evolve from being merely compliant and reliable to being strategic, adaptive, and intelligent.
We see several key forces shaping this transformation:
At Acnos, we view these shifts as opportunities to create value and resilience for our partners. Our mission is to bridge clinical innovation with operational excellence — ensuring that sponsors can execute complex global trials with full confidence in continuity, compliance, and patient safety. Looking ahead, we aim to play a pivotal role in shaping the future of clinical logistics — combining regulatory rigor with true agility. As the industry embraces decentralisation, digitalisation, and patient-centric research, Acnos will continue to evolve as a trusted partner and innovation driver, ensuring that every patient, in every corner of the world, receives the right medication at the right time. Our vision is to help transform the clinical supply chain into a smart, sustainable, and resilient ecosystem — one that empowers faster, more inclusive, and more reliable clinical research worldwide.
PGS: Can you briefly introduce your company?
Answer: A.P. Moller – Maersk is a global leader in integrated logistics, headquartered in Copenhagen, Denmark. Founded in 1904, Maersk operates in over 130 countries with more than 100,000 employees worldwide. The company offers end-to-end supply chain solutions, including ocean and inland transportation, freight forwarding, warehousing, customs services, and digital logistics platforms.
PGS: Highlight your core services and solutions within the pharma and clinical supply ecosystem?
Answer: Our capabilities include:
PGS: Which markets and regions do you primarily operate in, and how do these geographies influence your service capabilities?
Answer: We operate pharmaceutical logistics on a global scale, leveraging our robust cold chain infrastructure across key regions globally.
In Europe, our Rotterdam Maasvlakte Pharma Cold Store Facility (MV2) serves as the main central Hub, both for biological samples, clinical trial, API’s and general pharma distribution, supported by additional locations across the continent. This central hub enables us to provide highly compliant, efficient, and scalable solutions for life sciences customers.
Our strategic focus on MV2 responds to the growing demand for reliable, GDP-compliant cold chain solutions, ensuring precision and agility for clinical trials and commercial supply chains.
PGS: What differentiates your solutions from others in the industry, and how do you bring value to pharma clients, CROs, and CDMOs?
Answer: Maersk delivers integrated clinical trial logistics through GDP-compliant cold storage, temperature-controlled transport, and full supply chain visibility via our WMS.
Our MV2 Pharma Cold Store Facility is the cornerstone of our European operations, strategically located near major R&D and life science hubs, ensuring fast, secure, and compliant handling of pharmaceutical products, R&D and clinical research operations.
Bonded warehousing and in-house customs consultants, allow us to manage permits and licenses, accelerating clearance and reducing complexity. Combined with our infrastructure, agility, and end-to-end modular services, we bring reliability and value to pharma clients, CROs, and CDMOs.
PGS: What major challenges do you foresee for the pharma and clinical supply chain in the coming years, and how is your organization positioned to support and complement industry needs?
Answer: As R&D accelerates and AI enhances drug discovery, the pharma and clinical supply chain faces increasing complexity, demand for speed, and regulatory scrutiny. With the market growing steadily at 5% annually, scalability and reliability are critical. Maersk is positioned to support these needs through GDP-compliant infrastructure, anchored by our MV2 Pharma Cold Store Facility, we ensure agility, compliance, and end-to-end visibility.
PGS: How do you see the future of clinical research, logistics, and pharma operations evolving, and what role does your organization aim to play in shaping this future?
Answer: The future of clinical research and pharma logistics is being shaped by rapid digital transformation.
AI is accelerating drug discovery and enabling more targeted, efficient trials. Decentralized and Direct-to-Patient models are gaining traction, demanding greater flexibility, speed, and precision from logistics providers.
Real-time monitoring and control tower technologies are necessary to enhance visibility and resilience across the supply chain.
Maersk has been investing for decades in advanced logistics technologies to deliver full visibility and control across the entire supply chain.
Through our own Warehouse Management System (WMS) and strategic partnerships, we provide fully monitored, end-to-end cold chain solutions.
With our in-house IT tools, we are able to ensure efficient temperature monitoring and control, providing the highest level of safety, full traceability and visibility across the entire cold logistics chain.
PGS: Can you briefly introduce your company?
Answer: You can think of N-SIDE as a company of problem-solvers for very complex challenges. We started in Belgium back in 2000 and specialize in using advanced mathematical optimization and artificial intelligence to tackle industry problems. Currently, our main area of focus is the clinical supply chain, but we are also present in the energy industry, where we help power grid operators and energy markets navigate the transition to renewable energy and manage complex operations.
PGS: Highlight your core services and solutions within the pharma and clinical supply ecosystem?
Answer: N-SIDE provides a comprehensive clinical supply planning ecosystem designed to take the guesswork and chaos out of planning, using advanced analytics and AI. Our tools help biopharma companies plan along the chain, from manufacturing the drugs (Prediction app) to designing the trial (with simulations in the Supply app) and forecasting day-to-day trial needs (Lighthouse).
Our historical flagship solution is the Supply App – a simulation & optimization solution for clinical supply chain. With it, we can make a trial happen virtually, and optimize decisions to the point that we reduce drug waste by 40%, help solve drug shortages, and make the supply chain an enabler of fast clinical trial timelines. We have a team of over 70 experts who partner with companies to help them change their processes, train their teams, and make sure everything runs smoothly.
PGS: Which markets and regions do you primarily operate in, and how do these geographies influence your service capabilities?
Answer: Our business operations span Europe, North America, and the Asia-Pacific region. We work with over 50 biopharma in more than 20 countries. As customer support is part of our trademark, we have offices right where our customers are: headquarters in Belgium, offices in the USA (Cambridge, MA) and Japan (Tokyo).
PGS: What differentiates your solutions from others in the industry, and how do you bring value to biopharma companies, CROs, and CDMOs?
Answer: We are differentiated by 25 years of experience and continuous iterations on our forecasting and planning solutions. Our unique technology, grounded in advanced analytics, simulations and optimization, also sets us apart. We have decades of deep, practical knowledge in clinical supply chains that we put in practice in our partnerships, which run deep with our customers. Through our longevity, we have built very concrete business cases where we were able to reduce drug production or sourcing needs by up to 50% for our customers. We give companies the confidence to run trials using far less medicine, but without ever risking a patient missing a dose. This saves a massive amount of money, which companies can then reinvest into researching new treatments.
PGS: What major challenges do you foresee for the pharma and clinical supply chain in the coming years, and how is your organization positioned to support and complement industry needs?
Answer: It’s hard to choose one. But rising costs of raw materials, global drug shortages, the geopolitical situation, complexifying clinical trial designs, more ambitious timelines, more competitive indications, sustainability targets… All these trends have the same impact on clinical supply: they make our job an incrementally complicated puzzle to solve. Our solutions help make sense of all of these events, and propose CTS plans that cover the constraints, while ensuring no missed visits and lower waste.
We help companies build a resilient supply chain that’s ready for multiple futures (moving from being “reactive” to “proactive”). By providing a centralized, global view of the supply chain, we also get all the different teams (CMC, clinical, etc.) to stop working in silos and make decisions together (moving from “fragmented” to “integrated”).
PGS: How do you see the future of clinical research, logistics, and pharma operations evolving, and what role does your organization aim to play in shaping this future?
Answer: Due to the challenges mentioned before, clinical supply has shifted from being an operational, execution, role to a more strategic enabler. From a small cost center, to an area that now catches leadership’s eye. Due to this, CTS is thankfully blessed by a lot of innovation recently.
We aim to help identify which initiatives will have the largest ROI for our customers, and transform the way they handle their clinical supply chain. We want to standardize and simplify things in an industry that is admittedly known for causing headaches. But that is also why we love it – if it weren’t a challenge, there’d be nothing to optimize!
PGS: Can you briefly introduce your company?
Answer: KOOLIQ is part of the Engineered Foam Products company which specializes in molded foam products used in a variety of applications, mainly focused on impact protection, thermal insulation, and structural stability. We provide bespoke industrial and consumer product solutions across a wide range of industries, markets and consumer channels.
Having worked in many areas of thermal protective solutions over the years, KOOlIQ is our new to market Cold Chain shipping range designed and qualified specifically for the transportation of Pharmaceutical and Clinical Trial markets.
PGS: Highlight your core services and solutions within the pharma and clinical supply ecosystem?
Answer: KOOLIQ provide a range of Thermal Isolating parcel shippers, qualified to the exacting standards of ISTA 7d thermal stress profiles to provide solutions from 48 up to 140 hours qualified passive thermal protection.
KoolIQ is designed not just to provide the thermal protective performance required but to do so with best in class payload efficiency, use of common components and geometries driving simplicity in you logistics operations, and reduced initial investment and parts replacement costs through a focus on designing out unnecessary materials and inefficient re-use or requalification processes.
PGS: Which markets and regions do you primarily operate in, and how do these geographies influence your service capabilities?
Answer: We currently produce KOOLIQ in the UK and support mostly a European customer base but can supply globally as required.
PGS: What differentiates your solutions from others in the industry, and how do you bring value to pharma clients, CROs, and CDMOs?
Answer: KOOLIQ has the benefit of being developed recently using some of the best thermal modeling techniques available. This has allowed us to optimised payload sizes, material use and costs in our design process along with the very high thermal protective performance required in the industry. We believe this has allowed us to design efficiency into the KOOLIQ systems that translates to lowering supply chain costs for its users versus other older market systems that are not optimised from these three driving principles in their evolution.
PGS: What major challenges do you foresee for the pharma and clinical supply chain in the coming years, and how is your organization positioned to support and complement industry needs?
Answer: Lower cost, secure and environmentally sustainable cold chain logistics solutions are a key challenge. Re-usability reduces material waste but adds other costs of asset re qualification, recover and system loss.
KOOLIQ offers a range of prequalified cold chain shippers that lower the asset costs to deploy re-use solutions, simplifies requalification processes within the supply chain with free and open process support, and has modular designs allowing for efficient and low costs, easy assembled, component replacements.
PGS: How do you see the future of clinical research, logistics, and pharma operations evolving, and what role does your organization aim to play in shaping this future?
Answer: Future growth in clinical studies and of complex supply chains from increasingly individualised treatments will drive a greater need for efficient and effective cold chain distribution solutions. KOOLIQ can be part of that solution balancing performance, costs and efficiency on the journey from clinical studies through to complex commercial end user distribution of our clients pharmaceutical compounds.
